IsoPlexis to Report Third Quarter 2022 Financial Results on November 10, 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) — IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will report financial results for the third quarter 2022 before market open on Thursday, November 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event.

About IsoPlexis

IsoPlexis is empowering labs to leverage the cells and proteome changing the course of human health. Its platforms provide insights into how multi-functional immune cells communicate and respond, assisting researchers in understanding and predicting disease progression, treatment resistance and therapeutic efficacy.

IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies by revenue and 78% of leading U.S. comprehensive cancer centers.

Investor Contact
investors@isoplexis.com

Press Contact
press@isoplexis.com

Staff

Recent Posts

Kanazawa University research: Scientists develop a new method to measure cellular energy in real time

KANAZAWA, Japan, Nov. 20, 2025 /PRNewswire/ -- Researchers at the Nano Life Science Institute (WPI-NanoLSI),…

5 hours ago

Oracle Names Stephen Rusckowski to the Board of Directors

AUSTIN, Texas, Nov. 20, 2025 /PRNewswire/ -- Oracle Corporation (NYSE: ORCL) today announced that it…

5 hours ago

Onco-Innovations Advances Optimization and Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services to Support Future Phase 1 Clinical Studies

VANCOUVER, BC / ACCESS Newswire / November 20, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ)…

8 hours ago

GE HealthCare to acquire Intelerad, advancing cloud-enabled enterprise imaging across care settings

Creates a fully-connected, cloud-first imaging ecosystem spanning high-growth outpatient and ambulatory, teleradiology and hospital settings…

11 hours ago

GE HealthCare to acquire Intelerad, advancing cloud-enabled enterprise imaging across care settings

Creates a fully-connected, cloud-first imaging ecosystem spanning high-growth outpatient and ambulatory, teleradiology and hospital settings…

11 hours ago

Hyperfine, Inc. to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain…

11 hours ago